NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/01/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization10.09 mln
Float1.77 mln
Earnings Date08/12/2026
Piotroski F-Score
4
/ 9
Borderline
Beneish M-Score
-1.47
Manipulation likely
Relative Strength
83
/ 100
Strongly outperforming
Debt / Equity
1.12
Elevated leverage
ROE
-90.14
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Bolt Biotherapeutics is a clinical-stage company focused on developing new cancer treatments that harness the body's immune system. Their work centers on a range of experimental therapies targeting several cancer types, including stomach, lung, pancreatic, and breast cancers. The company works alongside partners such as Genmab, Toray Industries, and Innovent Biologics, and holds a licensing agreement with Stanford University. Founded in 2015 and based in Redwood City, California, Bolt Biotherapeutics aims to advance cancer care through innovative immune-based approaches.
